All News

988 Lifeline rollout linked to 11% drop in youth suicide deaths, with greater reductions in states with higher call uptake, study finds.

PFAS exposure, especially PFDA, was linked to higher nonmelanoma skin cancer odds, with stronger effects observed in older adults.

There was comparable 12-month fitness and functional outcomes in lymphoma survivors, suggesting a scalable option to expand access to cardio-oncology care.

Young-onset CRC mortality rose over 3 decades in the US, largely among adults with lower educational attainment, widening socioeconomic gaps.

A new AHIP report outlines evidence-based strategies to cut chronic disease prevalence by 10% by 2035.

The 5-year prediction of MS progression, defined by clinical and objective measurements, was possible with 2 machine learning tools.

Black Maternal Health Week spotlights disparities, Medicaid postpartum coverage gains, and ongoing policy efforts to reduce maternal mortality.

Subgroup data show no reduction in cardiovascular death or myocardial infarction—and a potential signal of harm—in highly frail patients.

Clinical trials are evolving toward decentralized, patient-centered models, but enrollment challenges, outdated protocols, and infrastructure gaps persist.

Tuan Vu, MD, explains the results of the NIMBLE trial, whose results will be presented at the American Academy of Neurology conference.

Food insecurity remains among children above SNAP limits, highlighting broad-based categorical eligibility gaps that exclude at-risk families just over eligibility thresholds.

DELTA 3 trial extension data show sustained improvements in disease-specific, dermatology-specific, and overall quality-of-life measures.

SPIRIT-HF reported neutral outcomes for spironolactone in HFpEF/HFmrEF, but ongoing analyses may clarify which patients benefit most.

A new study finds that highly lethal cancers receive less research support than lower-risk cancers.

LaShawn McIver, MD, MPH, discusses a new report from a task force aiming to cut chronic disease prevalence 10% by 2035 through prevention and coordinated care.

A new review explains how new therapies and technologies are guiding the treatment of acute myeloid leukemia (AML).

A new industry report underscores the momentum—and the work ahead—as gene-, cell-, and tissue-based treatments move from academic health systems into community care.

New myeloma therapies—CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina Varshavsky-Yanovsky, MD, PhD.

Previous inquiries into the associations between sleep disorders were limited by small sample sizes, according to researchers.

At 24 months, patients receiving iptacopan had approximately half the decline in estimated glomerular filtration rate slope compared to those receiving placebo.

Late diagnosis of hepatitis B and C remains common and is driven by factors like older age, male sex, comorbidities, and limited healthcare engagement.

Inconsistent use and wording of the “Not Better Explained” diagnostic criterion across major sleep disorder classifications may impact diagnostic accuracy, highlighting the need for greater standardization and clarity in clinical frameworks.

Patients with prescriptions that were initially rejected through prior authorization had more difficulty obtaining the treatment.

The 2026 Regional Diabetes Summit is taking place from April 28 to 29, 2026, in Wilmington, Delaware.

World Hemophilia Day spotlights the rare blood disorder that prevents the blood from clotting and can be dangerous when left untreated.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Patients who saw hair specialist dermatologists tended to be prescribed more therapies for their scarring alopecia.

Evidence suggests new therapies like GLP-1 receptor agonists, initially approved to treat obesity and diabetes, can also benefit patients with liver disease.